Mary Lake Polan - May 27, 2022 Form 4 Insider Report for QuidelOrtho Corp (QDEL)

Role
Director
Signature
/s/ Phillip S. Askim, attorney-in-fact for Mary Lake Polan
Stock symbol
QDEL
Transactions as of
May 27, 2022
Transactions value $
$0
Form type
4
Date filed
6/1/2022, 05:39 PM
Previous filing
May 20, 2022
Next filing
Jun 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QDEL Common Stock Award +20.7K 20.7K May 27, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QDEL Restricted Stock Units Award $0 +1.95K $0.00 1.95K May 27, 2022 Common Stock 1.95K Direct F2, F3, F4
transaction QDEL Restricted Stock Units Award $0 +1.22K $0.00 1.22K May 27, 2022 Common Stock 1.22K Direct F2, F3, F4
transaction QDEL Restricted Stock Units Award $0 +1.57K $0.00 1.57K May 27, 2022 Common Stock 1.57K Direct F2, F3, F4
transaction QDEL Restricted Stock Units Award $0 +1.42K $0.00 1.42K May 27, 2022 Common Stock 1.42K Direct F2, F3, F4
transaction QDEL Restricted Stock Units Award $0 +875 $0.00 875 May 27, 2022 Common Stock 875 Direct F2, F3, F4
transaction QDEL Restricted Stock Units Award $0 +262 $0.00 262 May 27, 2022 Common Stock 262 Direct F2, F3, F4
transaction QDEL Restricted Stock Units Award $0 +273 $0.00 273 May 27, 2022 Common Stock 273 Direct F2, F3, F4
transaction QDEL Restricted Stock Units Award $0 +82 $0.00 82 May 27, 2022 Common Stock 82 Direct F2, F3, F4
transaction QDEL Restricted Stock Units Award $0 +427 $0.00 427 May 27, 2022 Common Stock 427 Direct F2, F3, F4
transaction QDEL Restricted Stock Units Award $0 +128 $0.00 128 May 27, 2022 Common Stock 128 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho.
F2 Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock.
F3 Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F4 Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.